Pfizer (NYSE:PFE) Shares Up 2.3% – Should You Buy?

Shares of Pfizer Inc. (NYSE:PFE) shot up 2.3% during mid-day trading on Tuesday . The stock traded as high as $25.50 and last traded at $25.2450. 49,246,894 shares changed hands during trading, an increase of 17% from the average session volume of 42,244,516 shares. The stock had previously closed at $24.67.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Earnings beat anticipated: Analysts expect Pfizer to outperform consensus estimates for the upcoming second quarter, supported by favorable earnings and revenue trends. A better-than-expected report or stronger guidance could reinforce confidence in the recovery. Pfizer Expected to Beat Earnings Estimates
• Positive Sentiment: Oncology pipeline could broaden growth: The FDA’s Priority Review of TALZENNA with XTANDI in an earlier prostate-cancer setting could expand Pfizer’s precision-oncology franchise if approved. The opportunity helps offset concerns about declining COVID-product sales and future patent expirations. FDA Priority Review of TALZENNA and XTANDI
• Positive Sentiment: Value investors remain interested: Commentary highlights Pfizer’s low valuation and dividend appeal, with some investors arguing that the stock has fallen too far despite a real patent-cliff risk. This value-oriented view is helping support the shares. Pfizer Patent Cliff and Valuation
• Neutral Sentiment: Ibuzatrelvir Phase 1 update: Pfizer completed a Phase 1 study and refined the tablet formulation. The update advances development of the antiviral candidate, but early-stage data do not yet establish efficacy or a near-term financial contribution. Pfizer Ibuzatrelvir Phase 1 Study
• Negative Sentiment: Longer-term risks remain: Pfizer still faces revenue pressure from the COVID-product decline and upcoming patent losses. Investors are watching whether its cancer, obesity, and other pipeline programs can replace that revenue quickly enough.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley upped their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Finally, HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Stock Performance

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average price of $25.10 and a two-hundred day moving average price of $26.17. The company has a market capitalization of $143.88 billion, a price-to-earnings ratio of 19.27 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently modified their holdings of the company. Evolution Wealth Management Inc. boosted its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter valued at $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $26,000. YANKCOM Partnership purchased a new position in shares of Pfizer during the 4th quarter worth $28,000. Finally, HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.